FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Semaglutide Trial for Hypothalamic Obesity in Craniopharyngioma Patients Aged 12 to 17 Years Set to Begin
研究ライブラリに戻る

Semaglutide Trial for Hypothalamic Obesity in Craniopharyngioma Patients Aged 12 to 17 Years Set to Begin

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Semaglutide Trial for Hypothalamic Obesity in Craniopharyngioma Patients Aged 12 to 17 Years Set to Begin

A new clinical trial is set to explore the potential benefits of semaglutide, a GLP-1 receptor agonist, as an intervention for managing hypothalamic obesity in children and adolescents aged 12 to 17 years who have undergone treatment for craniopharyngioma. The study, titled "SEMAFORCRANIO," is scheduled to begin recruitment soon at the University Hospital of Angers.

Craniopharyngiomas are rare brain tumors that develop near the pituitary gland and can cause severe complications due to their location in the brain. One of the most significant long-term issues faced by patients with craniopharyngioma is hypothalamic obesity, which often results from damage to the hypothalamus during tumor removal or radiation therapy. This condition leads to rapid weight gain that is difficult to manage through conventional means.

The SEMAFORECRANIO trial aims to evaluate whether semaglutide can help mitigate this severe side effect by targeting appetite regulation and metabolism in young patients who have experienced hypothalamic damage from craniopharyngioma treatment. Semaglutide, marketed under the brand name Wegovy for weight management in adults, has shown promise in clinical settings for its ability to reduce food intake and promote satiety.

Background

Craniopharyngiomas are rare tumors that typically occur during childhood or adolescence but can also develop later in life. These benign tumors often require surgical intervention followed by radiation therapy to prevent recurrence. However, the treatment can lead to significant damage to surrounding brain tissue, including the hypothalamus, which regulates hunger and metabolism.

Hypothalamic obesity is a serious complication that affects many patients who have undergone treatment for craniopharyngioma. This condition can result in rapid weight gain and severe metabolic issues, significantly impacting quality of life and long-term health outcomes. Current treatments are limited, making the development of new therapeutic options critical.

Key Details

The SEMAFORECRANIO trial is a multicenter, double-blind, parallel, randomized controlled study designed to assess the efficacy of semaglutide in managing hypothalamic obesity in children and adolescents aged 12 to 17 years. The trial will compare weekly injections of semaglutide with placebo over an extended period.

Participants will be randomly assigned to receive either semaglutide or a placebo, with neither patients nor researchers aware which treatment is being administered. This design ensures unbiased evaluation of the drug's effectiveness and safety in this specific patient population. The study aims to recruit 120 participants across multiple centers, providing robust data on the potential benefits and risks associated with semaglutide use.

Key Takeaways

  • Semaglutide Shows Promise: Early research suggests that semaglutide may help manage hypothalamic obesity in patients who have undergone treatment for craniopharyngioma.
  • Multicenter Collaboration: The trial involves multiple centers, ensuring a broad and diverse participant pool to validate findings across different settings.
  • Placebo-Controlled Design: A placebo-controlled study design will provide clear evidence of semaglutide's efficacy compared to no intervention.
  • Long-Term Follow-Up: Comprehensive follow-up assessments are planned to evaluate the long-term effects of semaglutide on weight management and metabolic health.

What This Means

The SEMAFORECRANIO trial represents a significant step forward in addressing one of the most challenging complications associated with craniopharyngioma treatment. If successful, this research could pave the way for new therapeutic options that improve quality of life and long-term outcomes for young patients dealing with hypothalamic obesity.

For the peptide community, this study highlights the potential of GLP-1 receptor agonists like semaglutide in managing severe metabolic disorders beyond traditional weight management. The findings from SEMAFORECRANIO could also inform future research into other applications of peptide therapy and contribute to a deeper understanding of hypothalamic function.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。